Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The study, Step-Up HS, will evaluate Rinvoq ...

The latest announcement is out from Ultragenyx Pharmaceutical ( ($RARE) ). On December 29, 2025, Ultragenyx reported Phase 3 results from its ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART.

While the third act of Avengers: Endgame could make this the most entertaining of the third Phase alone, this entry in The ...